Cantor Fitzgerald’s Larimar Therapeutics LRMR Stock Holding History

Cantor Fitzgerald’s Portfolio LRMR Stock Details LRMR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-127,500	Closed	-$412K	–	303
2025 Q3	$412K	Buy	+127,500	New	+$478K	﹤0.01%	308

Other funds holding LRMR

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Cantor Fitzgerald's LRMR Position: Q4 2025 in Review

Cantor Fitzgerald sold out of Larimar Therapeutics (LRMR) in Q4 2025, closing a stake of 127,500 shares — an estimated $412K sold.

Cantor Fitzgerald first reported a position in LRMR in Q3 2025 and held it in 1 quarter. The position peaked at $412K in Q3 2025. 136 funds tracked by Wall St. Rank hold LRMR as of Q4 2025.

Cantor Fitzgerald reported no remaining Larimar Therapeutics position as of Q4 2025 after selling out during the quarter.
Cantor Fitzgerald sold 127,500 Larimar Therapeutics shares in Q4 2025, an estimated $412K.
Cantor Fitzgerald first reported a position in Larimar Therapeutics in Q3 2025 and held it in 1 quarter.
Cantor Fitzgerald's Larimar Therapeutics position peaked at $412K in Q3 2025.
136 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q4 2025.

Based on Cantor Fitzgerald's 13F filing for Q4 2025, filed 17 Feb 2026.